Cargando…

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone

BACKGROUND: Chondrosarcoma is a malignant cartilage forming bone tumour for which no effective systemic treatment is available. Previous studies illustrate the need for a better understanding of the role of the IGF pathway in chondrosarcoma to determine if it can be a target for therapy, which was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterse, Elisabeth F. P., Cleven, Arjen H. G., De Jong, Yvonne, Briaire-de Bruijn, Inge, Fletcher, Jonathan A., Danen, Erik H. J., Cleton-Jansen, Anne-Marie, Bovée, Judith V. M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946092/ https://www.ncbi.nlm.nih.gov/pubmed/27418340 http://dx.doi.org/10.1186/s12885-016-2522-8

Ejemplares similares

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
por: Cleven, Arjen H. G., et al.
Publicado: (2017)

Targeting survivin as a potential new treatment for chondrosarcoma of bone
por: de Jong, Y, et al.
Publicado: (2016)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
por: de Jong, Yvonne, et al.
Publicado: (2019)

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
por: de Jong, Yvonne, et al.
Publicado: (2019)

SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone
por: Kroonen, Jessie S., et al.
Publicado: (2021)

Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours
por: Cleven, Arjen H. G., et al.
Publicado: (2022)

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
por: Sundara, Yayan T., et al.
Publicado: (2016)

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma
por: Lam, Suk Wai, et al.
Publicado: (2019)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
por: Palubeckaitė, Ieva, et al.
Publicado: (2020)

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
por: Kuijjer, Marieke L, et al.
Publicado: (2013)

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
por: Lam, Suk Wai, et al.
Publicado: (2019)

High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
por: Lou, Sha, et al.
Publicado: (2016)

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
por: Kostine, Marie, et al.
Publicado: (2017)

Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors: A Common Genomic Abnormality in Vascular Malformation/Hemangioma and Simple Bone Cyst
por: Ong, Sheena L.M., et al.
Publicado: (2021)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

CORR Insights(®): Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma
por: Peterse, Elisabeth F. P., et al.
Publicado: (2015)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
por: Franceschini, Natasja, et al.
Publicado: (2021)

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro
por: Schrage, Yvonne M, et al.
Publicado: (2009)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
por: Franceschini, Natasja, et al.
Publicado: (2021)

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option
por: Willems, Stefan M, et al.
Publicado: (2010)

BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors
por: Boeuf, Stephane, et al.
Publicado: (2012)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas
por: van IJzendoorn, David G. P., et al.
Publicado: (2019)

Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

Correction: Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
por: Addie, Ruben D., et al.
Publicado: (2019)

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging
por: Lou, Sha, et al.
Publicado: (2016)

Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation
por: de Andrea, Carlos E., et al.
Publicado: (2011)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

In vitro studies of osteosarcoma: A researcher's perspective of quantity and quality
por: Peterse, Elisabeth F.P., et al.
Publicado: (2017)

What’s new in bone forming tumours of the skeleton?
por: Franceschini, Natasja, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jnu67jaglej7ui4tnkr4im3bs2